Abstract | BACKGROUND: METHODS AND PARTICIPANTS: In this placebo-controlled double-blinded study 36 non-diabetic patients with stable ischemic CHF (age 63 ± 9 years, peak VO(2) 16.6 ± 4.8 ml/kg/min, LVEF 32 ± 9%) were randomized to irbesartan 300 mg/d vs placebo on top of standard CHF therapy. Body composition (dual energy X-ray absorptiometry), clinical status, peripheral vasodilator capacity (plethysmography) and neuroendocrine and metabolic profiles were assessed. Primary endpoint was the change of whole body insulin sensitivity after 4 months of treatment assessed by intravenous glucose tolerance testing and minimal modeling. RESULTS:
Insulin sensitivity improved by 26% (p<0.001) in the irbesartan group, but not in the placebo group (treatment effect: 1.044 min(-1)·μU·ml(-1)·10(4); 95%CI 0.45 to 1.64, p=0.0026). Treatment effects on systolic and diastolic blood pressure were -11 (95%CI -21 to -1)mmHg and -8 (95%CI -15 to -3)mmHg, respectively. Peripheral vasodilator capacity improved by 14% (p=0.016). Change in insulin sensitivity correlated with increased vasodilator capacity (R=0.47, p=0.021). Body composition and clinical status were not different after 4 months of therapy. Also adiponectin, resistin, cytokine profile, and asymmetric dimethylarginine (ADMA) were not changed after this short-term intervention. CONCLUSION:
|
Authors | Wolfram Doehner, Johanna Todorovic, Cornelia Kennecke, Mathias Rauchhaus, Anja Sandek, Mitja Lainscak, Sophie van Linthout, Carsten Tschöpe, Stephan von Haehling, Stefan D Anker |
Journal | International journal of cardiology
(Int J Cardiol)
Vol. 161
Issue 3
Pg. 137-42
(Nov 29 2012)
ISSN: 1874-1754 [Electronic] Netherlands |
PMID | 21856022
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Angiotensin Receptor Antagonists
- Biphenyl Compounds
- Tetrazoles
- Irbesartan
|
Topics |
- Aged
- Angiotensin Receptor Antagonists
(pharmacology, therapeutic use)
- Biphenyl Compounds
(pharmacology, therapeutic use)
- Double-Blind Method
- Female
- Heart Failure, Systolic
(blood, drug therapy, physiopathology)
- Humans
- Insulin Resistance
(physiology)
- Irbesartan
- Male
- Middle Aged
- Prospective Studies
- Tetrazoles
(pharmacology, therapeutic use)
- Vasodilation
(drug effects, physiology)
|